JEFFERSONVILLE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Jeffersonville Bancorp, Inc. (OTCQB - JFBC) announced today third quarter net income of $3,293,000 or $0.78 per share compared to $3,092,000 or $0.73 per share for the same quarter in 2024. The increase in quarterly net income compared to 2024 of $201,000 was primarily attributable to a reduction in interest expense of $554,000 and an increase of $500,000 in loan interest and fees, partially offset by a reduction in other interest and dividend income o ...

VOCL, providing creators monetization for worldwide audiences by directly supporting their content, empowering independent media, and engagement at every level without the censorshipChaska, MN, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mike Lindell Media Corp. (MLMC), LindellTV, and VOCL Social experienced explosive growth with the downloading of the VOCL app over the last Quarter, doubling it's user base and accelerating engagement across the platform. The surge directly correlates with the livestreaming of Lindel ...

LODI, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Farmers & Merchants Bancorp (OTCQX: FMCB) (the “Company” or “FMCB”), the parent company of Farmers & Merchants Bank of Central California (the “Bank” or “F&M Bank”), announced today that it will temporarily offer a special voluntary program through which shareholders owning 99 shares or less of FMCB common stock, as of November 12, 2025, may sell all of their shares without paying any fees. This program allows eligible shareholders to easily sell all their sha ...

Core Insights - Future has appointed Michael Peralta as the new Chief Revenue Officer, effective December 3, 2025, to lead its global commercial organization [2][3] - The appointment aligns with Future's strategy to leverage AI, first-party data, and Retail Media Networks to enhance value for partners [3][4] Company Strategy - Future is focusing on diversifying its offerings across advertising, e-commerce, RMN, and emerging AI and data partnerships [4] - The company aims to unite its strengths to drive sustainable growth and deliver unmatched value for advertisers and partners [4] Leadership Background - Michael Peralta has extensive experience in media and technology, previously serving as Vice President and General Manager of T-Mobile Advertising Solutions [5] - He has held senior roles at various companies, including Criteo, AudienceScience, MediaMath, and AOL/Advertising.com, recognized for building data-driven, scalable products [5] Educational Background - Peralta holds a Bachelor of Science degree in Environmental Engineering from Rensselaer Polytechnic Institute and has pursued graduate studies in Management and Public Policy at New York University [6]

Infographic 1 Infographic 1 Infographic 2 Infographic 2 Infographic 3 Infographic 3 Infographic 4 Infographic 4 Infographic 5 Infographic 5 Infographics accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ec2df2de-dfb1-4a07-8407-651fd33a4858 https://www.globenewswire.com/NewsRoom/AttachmentNg/9eb0fcd5-0106-4902-987f-4d7ff49ce32a https://www.globenewswire.com/NewsRoom/AttachmentNg/3aee281a-bd31-48c9-aae4-8122c1e3b6b1 https://www.globenewswi ...

Core Insights - Kelyniam Global, Inc. has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material for cranial, craniofacial, and maxillofacial implants, with a two-year exclusivity period and an option for renewal [1][2][3] Company Developments - The incorporation of VESTAKEEP® Fusion enhances Kelyniam's regenerative product lineup by leveraging its osteoconductive properties, which promote human bone growth and integration [2][4] - This strategic move is expected to add significant value for shareholders by expanding Kelyniam's regenerative medicine portfolio, positioning the company to meet the increasing demand for innovative cranial reconstruction solutions [3][4] Product and Market Positioning - Kelyniam's partnership with Modern Plastics ensures reliable access to PEEK materials, supporting the company's growth in advanced neurosurgical solutions [2][3] - The introduction of VESTAKEEP® Fusion reflects Kelyniam's commitment to delivering regenerative technologies that improve patient outcomes and advance the standard of care in cranial and craniofacial solutions [4]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

Press release – Neuilly-sur-Seine, Thursday, November 13, 2025 – 6.30 pm ARGAN and DIMOLOG officially inaugurated the new AutOnom® logistics site in Bain-de-Bretagne A few months after the delivery of the AutOnom® logistics site in Bain-de-Bretagne, ARGAN — the French real estate company specializing in the development and rental of premium warehouses — and its tenant DIMOLOG officially celebrated its inauguration during a friendly ceremony that brought together nearly one hundred participants. Mrs. Myriam ...

Paris, 13 November 2025 Capitalised terms used herein shall have the meaning specified for such terms in the Caisse Française de Financement Local base prospectus to the €75,000,000,000 Euro Medium Term Note Programme dated 10 June 2025 (the “Base Prospectus”). Caisse Française de Financement Local has decided to issue on 17 November 2025 – Euro 150,000,000 Fixed Rate Obligations Foncières due 17 May 2039 to be assimilated upon listing and form a single series with the existing Euro 500,000,000 Fixed Rate O ...

Core Insights - Legend Biotech has officially opened a new 31,000-square-foot R&D facility in Philadelphia, enhancing its position as a leader in cell therapy innovation [3][4][5] - The facility will support the development of CAR-T therapies for oncology and immunology indications, contributing to Legend's expanding pipeline of next-generation cell therapies [4][5][9] Company Overview - Legend Biotech is headquartered in Somerset, New Jersey, and employs over 2,900 individuals, making it the largest standalone cell therapy company [9] - The company is known for its CARVYKTI treatment for relapsed or refractory multiple myeloma, which has been administered to over 9,000 patients across 132 treatment centers in 44 states [9] Facility Details - The new Philadelphia facility features advanced laboratories and collaborative workspaces aimed at fostering innovation and accelerating research programs [4][5] - Approximately 55 full-time employees will work at the new site, which complements Legend's existing R&D presence in Piscataway, New Jersey [5][6] Industry Context - The opening of the facility reflects the strength of Philadelphia's life sciences ecosystem, which is home to top-tier scientific talent and research institutions [8] - Local officials and industry leaders have expressed enthusiasm for Legend Biotech's investment, highlighting its potential to create high-quality jobs and enhance the city's reputation in healthcare innovation [8]